Relapsed Myeloma: Navigating Post-BCMA Therapy Failure
Description
Join us for an insightful discussion with Drs. Natalia Neparidze and Saad Z. Usmani as we explore treatment strategies for relapsed multiple myeloma following BCMA-targeted therapy failure. With CAR T-cell therapy and bispecific antibodies revolutionizing myeloma treatment, clinicians are now faced with new challenges as patients relapse after BCMA-directed therapies.
Through the case of a 62-year-old woman who relapsed one year post-BCMA CAR T-cell therapy, we will discuss mechanisms of resistance, treatment sequencing, and the role of novel agents like selinexor-pomalidomide-dexamethasone. This episode will provide hematologists with practical strategies to navigate post-BCMA treatment failure and optimize patient outcomes.
Learning Objectives
- Understand mechanisms of resistance and progression following BCMA-targeted therapy.
- Explore non-BCMA treatment options, including alternative targets and novel agents.
- Recognize key factors influencing treatment selection and patient management.
United States
